EHA: European Hematology Association

Conference Coverage

ESA benefits lower-risk MDS patients

COPENHAGEN—The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic...

Pages